Future of treatment for low-risk prostate cancer: for all, for some, or for none?
نویسنده
چکیده
ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors. Employment or Leadership Position: None Consultant or Advisory Role: Alberto F. Sobrero, Bayer (C), Amgen (C), Roche (C), Merck Serono (C), Astra Zeneca (C), sanofi-aventis (C) Stock Ownership: None Honoraria: Alberto F. Sobrero, Roche, Merck Serono, sanofi-aventis Research Funding: None Expert Testimony: None Other Remuneration:None
منابع مشابه
PSA Screening in Prostate Cancer
Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...
متن کاملEarly toxicity of moderate hypofractionated volumetric modulated Arc radiotherapy for localized prostate cancer
Background: Based on the radiation biology model of prostate cancer, hypofractionated radiotherapy can improve the treatment outcomes without increasing toxicity. Although hypofractionated radiotherapy is implemented over a short period of time, it is more convenient and cheaper compared with conventional fractionated treatment. The aim of this study was to investigate the early toxicity of mod...
متن کاملProstate-specific antigen kinetics after hypofractionated stereotactic body radiotherapy for localized prostate cancer
Background: stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized. The objective of the current study is to analyze the rate of PSA decline and PSA nadir following hypofractonated SBRT in localized prostate cancer. Materials and Methods: From 2008...
متن کاملUtility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223
A 76-year-old man with symptomatic bone metastases from castrationresistant prostate cancer underwent Radium-223-dichloride (Ra-223) therapy. Before Ra-223 therapy, he had normal peripheral blood cell counts. Ra-223 therapy relieved his shoulder and low back pain. The elevation of the serum prostate-specific antigen (PSA), doubling every month during Ra-223 therapy, suggested a PSA flare or rel...
متن کاملژنتیک مولکولی، تشخیص، پیشگیری و ژن درمانی در سرطان پروستات: مقاله مروری
The prostate is a small gland located below the bladder and upper part of the urethra. In developed countries prostate cancer is the second common cancer (after skin cancer), and also the second leading cause of cancer death (after lung cancer) among men. The several studies have been shown prostate cancer familial aggregation. The main reason for this aggregation is inheritance included genes....
متن کامل[68Ga]Ga-PSMA-11 PET/CT for staging and patient management of high-risk prostate cancer: A single-center experience from Iran
Introduction: Accurate staging plays an important role in management of patients with prostate cancer especially in high-risk group. Today, [68Ga]Ga-PSMA-11 PET/CT should be considered as the preferred imaging tool for treatment planning and initial staging of the disease. Methods: A total number of 628 patients with prostate cancer referred to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
دوره 29 15 شماره
صفحات -
تاریخ انتشار 2011